All inspectors · Key sources (PDF) · STEMI shock sheet (PDF)
The STEMI with cardiogenic shock one-pagerOpen it in a new tab

The patient in front of you

Mr. R., 64, arrives with an anterior STEMI and is already in shock: systolic pressure in the 80s on norepinephrine, lactate rising, ejection fraction about 25% on echo. He is awake and following commands. Suppose that, despite an opened culprit artery, he keeps deteriorating and is intubated and placed on VA-ECMO in the cardiac ICU. The shock course follows him from the cath lab to the ICU; each trial answers one decision in his care.

This page helps you decide: If he ends up on ECMO, should he be cooled?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

For Mr. R., if he ends up intubated on VA-ECMO, HYPO-ECMO does not justify cooling him to improve survival: 30-day death was 42% vs 51%, but the primary endpoint was not met, so normothermia at 36–37 °C, the trial's control strategy, remains the default; 24 hours of cooling for another reason did not add bleeding or infection. On the one-pager it sits on page 2, in the “Temporary mechanical support in AMI shock — what the randomized trials show” table (VA-ECMO row, harms and caveats column).